A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis

Arthritis and Rheumatism

Volumn 43, Issue 10, 2000, Pages 2316-2327

  Choi, Hyon K ^a   Seeger, John D ^b   Kuntz, Karen M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DRUG COST; DRUG EFFICACY; HUMAN; OUTCOMES RESEARCH; PAIN; PHYSICAL DISABILITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SIDE EFFECT;

ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; HUMANS; METHOTREXATE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0033784033     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6     Document Type: Article

References (29)

1. The economic cost and social and psychological impact of musculoskeletal conditions
2. Economics of rheumatoid arthritis
3. Methotrexate and emerging therapies
4. Efficacy of low-dose methotrexate in rheumatoid arthritis
5. Economic consequences of the progression of rheumatoid arthritis in Sweden
6. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
7. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis: The Methotrexate-Cyclosporine Combination Study Group
8. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate
9. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
10. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
11. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis
12. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model
13. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis
14. Measurement of patient outcome in arthritis
15. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline
16. The natural history of rheumatoid arthritis
17. Factors predicting response to treatment in rheumatoid arthritis: The importance of disease duration
18. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?
19. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis
20. Methotrexate(M)-hydroxychloroquine(H)-sulfasalazine(S) versus M-H or M-S for rheumatoid arthritis: Results of a double-blind study
21. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
22. Longterm treatment of DMARD failing rheumatoid arthritis patients with TNF recetor p 75 Fc fusion protein (TNFR:Fc; ENBREL)
23. Combination DMARD therapy with methotrexate-sulfasalazine-hydroxychloroquine in rheumatoid arthritis: Continued efficacy with minimal toxicity at 5 years
24. The total costs of drug therapy for rheumatoid arthritis: A model based on costs of drug, monitoring, and toxicity
25. Guidelines for monitoring drug therapy in rheumatoid arthritis
26. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates